Insmed Incorporated (INSM) has a consensus analyst rating of Buy, based on 34 analysts covering the stock. Of those, 32 recommend buying, 1 recommend holding, and 1 recommend selling.
The analyst consensus price target for INSM is $216.39, representing a +41.1% upside from the current price of $153.4. Price targets range from a low of $166.00 to a high of $269.00.
